Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

THE 2 COMPONENTS OF ANORO, LAMA AND LABA, WORK TOGETHER TO INCREASE BRONCHODILATION1

 

Adverse Reactions

ANORO is for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

ANORO is NOT for the relief of acute bronchospasm or for asthma.

Reference: 1. Cazzola M, Molimard M. The scientific rationale for combining long-acting ß2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257-267.